SAB Biotherapeutics (NASDAQ:SABS) Announces Quarterly Earnings Results, Beats Estimates By $0.38 EPS

SAB Biotherapeutics (NASDAQ:SABS) posted its quarterly earnings results on Friday. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.38, Zacks reports.

SAB Biotherapeutics Stock Performance

Shares of SABS traded up $0.14 during mid-day trading on Friday, hitting $3.24. 266,725 shares of the company’s stock were exchanged, compared to its average volume of 257,585. The company has a current ratio of 0.87, a quick ratio of 0.87 and a debt-to-equity ratio of 0.27. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The business’s 50 day moving average is $2.59 and its two-hundred day moving average is $2.23. The firm has a market capitalization of $33.73 million, a P/E ratio of -0.81 and a beta of 0.60.

Institutional Trading of SAB Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC purchased a new stake in shares of SAB Biotherapeutics during the third quarter worth approximately $30,000. Dimensional Fund Advisors LP acquired a new stake in SAB Biotherapeutics in the third quarter valued at about $32,000. Finally, Virtu Financial LLC acquired a new position in SAB Biotherapeutics during the 3rd quarter worth approximately $40,000. 7.82% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SABS has been the subject of several recent analyst reports. Wall Street Zen upgraded SAB Biotherapeutics to a “sell” rating in a research note on Saturday, September 20th. Leerink Partners started coverage on shares of SAB Biotherapeutics in a report on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SAB Biotherapeutics in a research report on Tuesday. HC Wainwright reduced their price target on shares of SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Finally, Leerink Partnrs upgraded SAB Biotherapeutics to a “strong-buy” rating in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.33.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.